Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Kah-Whye Peng

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Chemicals & Drugs

Anatomy

Procedures

Disorders

Multiple Myeloma

Physiology

Virus Replication

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Dingli D; Offord C; Myers R; Peng K-W; Carr T W; Josic K; Russell S J; Bajzer Z
Dynamics of multiple myeloma tumor therapy with a recombinant measles virus.
Frecha Cecilia; Costa Caroline; Lévy Camille; Nègre Didier; Russell Stephen J; Maisner Andrea; Salles Gilles; Peng Kah-Whye; Cosset Francois-Loïc; Verhoeyen Els
Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors.
Peng Kah-Whye; Dogan Ahmet; Vrana Julie; Liu Chunsheng; Ong Hooi T; Kumar Shaji; Dispenzieri Angela; Dietz Allan B; Russell Stephen J
Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Kah-Whye Peng (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Dingli D; Offord C; Myers R; Peng K-W; Carr T W; Josic K; Russell S J; Bajzer Z
Dynamics of multiple myeloma tumor therapy with a recombinant measles virus.
Cancer gene therapy 2009;16(12):873-82.
2009: Frecha Cecilia; Costa Caroline; Lévy Camille; Nègre Didier; Russell Stephen J; Maisner Andrea; Salles Gilles; Peng Kah-Whye; Cosset Francois-Loïc; Verhoeyen Els
Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors.
Blood 2009;114(15):3173-80.
2009: Peng Kah-Whye; Dogan Ahmet; Vrana Julie; Liu Chunsheng; Ong Hooi T; Kumar Shaji; Dispenzieri Angela; Dietz Allan B; Russell Stephen J
Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.
American journal of hematology 2009;84(7):401-7.
2009: Liu Chunsheng; Hasegawa Kosei; Russell Stephen J; Sadelain Michel; Peng Kah-Whye
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
The Prostate 2009;69(10):1128-41.
2009: Ong Hooi Tin; Trejo Theodore R; Pham Linh D; Oberg Ann L; Russell Stephen J; Peng Kah-Whye
Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo.
Molecular therapy : the journal of the American Society of Gene Therapy 2009;17(6):1012-21.
2009: Pham Linh; Nakamura Takafumi; Gabriela Rosales A; Carlson Stephanie K; Bailey Kent R; Peng Kah-Whye; Russell Stephen J
Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome.
The journal of gene medicine 2009;11(3):197-206.
2009: Russell S J; Peng K W
Measles virus for cancer therapy.
Current topics in microbiology and immunology 2009;330():213-41.
2008: Wang Hongjie; Liu Ying; Li Zongyi; Tuve Sebastian; Stone Daniel; Kalyushniy Oleksandr; Shayakhmetov Dmitry; Verlinde Christophe L M; Stehle Thilo; McVey John; Baker Andrew; Peng Kah-Whye; Roffler Steve; Lieber André
In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46.
Journal of virology 2008;82(21):10567-79.
2008: Russell Stephen J; Peng Kah Whye
The utility of cells as vehicles for oncolytic virus therapies.
Current opinion in molecular therapeutics 2008;10(4):380-6.
2007: Myers R M; Greiner S M; Harvey M E; Griesmann G; Kuffel M J; Buhrow S A; Reid J M; Federspiel M; Ames M M; Dingli D; Schweikart K; Welch A; Dispenzieri A; Peng K-W; Russell S J
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.
Clinical pharmacology and therapeutics 2007;82(6):700-10.
2007: Hasegawa Kosei; Hu Chunling; Nakamura Takafumi; Marks James D; Russell Stephen J; Peng Kah-Whye
Affinity thresholds for membrane fusion triggering by viral glycoproteins.
Journal of virology 2007;81(23):13149-57.
2007: Russell Stephen J; Peng Kah-Whye
Viruses as anticancer drugs.
Trends in pharmacological sciences 2007;28(7):326-33.
2007: Paraskevakou Georgia; Allen Cory; Nakamura Takafumi; Zollman Paula; James C David; Peng Kah Whye; Schroeder Mark; Russell Stephen J; Galanis Evanthia
Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas.
Molecular therapy : the journal of the American Society of Gene Therapy 2007;15(4):677-86.
2007: Haralambieva Iana; Iankov Ianko; Hasegawa Kosei; Harvey Mary; Russell Stephen J; Peng Kah-Whye
Engineering oncolytic measles virus to circumvent the intracellular innate immune response.
Molecular therapy : the journal of the American Society of Gene Therapy 2007;15(3):588-97.
2007: Ong H T; Hasegawa K; Dietz A B; Russell S J; Peng K-W
Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
Gene therapy 2007;14(4):324-33.
2006: Allen Cory; Vongpunsawad Sompong; Nakamura Takafumi; James C David; Schroeder Mark; Cattaneo Roberto; Giannini Caterina; Krempski James; Peng Kah-Whye; Goble Jenny M; Uhm Joon H; Russell Stephen J; Galanis Evanthia
Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.
Cancer research 2006;66(24):11840-50.
2006: Blechacz Boris; Splinter Patrick L; Greiner Suzanne; Myers Rae; Peng Kah-Whye; Federspiel Mark J; Russell Stephen J; LaRusso Nicholas F
Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Hepatology (Baltimore, Md.) 2006;44(6):1465-77.
2006: Hasegawa Kosei; Nakamura Takafumi; Harvey Mary; Ikeda Yasuhiro; Oberg Ann; Figini Mariangela; Canevari Silvana; Hartmann Lynn C; Peng Kah-Whye
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6170-8.
2006: Peng K-W; Hadac E M; Anderson B D; Myers R; Harvey M; Greiner S M; Soeffker D; Federspiel M J; Russell S J
Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model.
Cancer gene therapy 2006;13(8):732-8.
2006: Ong Hooi Tin; Timm Michael M; Greipp Philip R; Witzig Thomas E; Dispenzieri Angela; Russell Stephen J; Peng Kah-Whye
Oncolytic measles virus targets high CD46 expression on multiple myeloma cells.
Experimental hematology 2006;34(6):713-20.
2006: Goel Apollina; Dispenzieri Angela; Geyer Susan M; Greiner Suzanne; Peng Kah-Whye; Russell Stephen J
Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma.
Blood 2006;107(10):4063-70.
2006: Hasegawa Kosei; Pham Linh; O'Connor Michael K; Federspiel Mark J; Russell Stephen J; Peng Kah-Whye
Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(6):1868-75.
2005: Dingli David; Peng Kah-Whye; Harvey Mary E; Vongpunsawad Sompong; Bergert Elizabeth R; Kyle Robert A; Cattaneo Roberto; Morris John C; Russell Stephen J
Interaction of measles virus vectors with Auger electron emitting radioisotopes.
Biochemical and biophysical research communications 2005;337(1):22-9.
2005: Myers Rae; Greiner Suzanne; Harvey Mary; Soeffker Diane; Frenzke Marie; Abraham Katalin; Shaw Alan; Rozenblatt Shmuel; Federspiel Mark J; Russell Stephen J; Peng Kah-Whye
Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer.
Cancer gene therapy 2005;12(7):593-9.
2005: Nakamura Takafumi; Peng Kah-Whye; Harvey Mary; Greiner Suzanne; Lorimer Ian A J; James Charles D; Russell Stephen J
Rescue and propagation of fully retargeted oncolytic measles viruses.
Nature biotechnology 2005;23(2):209-14.
2004: Hadac Elizabeth M; Peng Kah-Whye; Nakamura Takafumi; Russell Stephen J
Reengineering paramyxovirus tropism.
Virology 2004;329(2):217-25.
2004: Allen Cory; McDonald Cari; Giannini Caterina; Peng Kah Whye; Rosales Gabriela; Russell Stephen J; Galanis Evanthia
Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
The journal of gene medicine 2004;6(11):1216-27.
2004: Peng K-W; Holler P D; Orr B A; Kranz D M; Russell S J
Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor.
Gene therapy 2004;11(15):1234-9.
2004: Anderson Bambi D; Nakamura Takafumi; Russell Stephen J; Peng Kah-Whye
High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus.
Cancer research 2004;64(14):4919-26.
2004: Nakamura Takafumi; Peng Kah-Whye; Vongpunsawad Sompong; Harvey Mary; Mizuguchi Hiroyuki; Hayakawa Takao; Cattaneo Roberto; Russell Stephen J
Antibody-targeted cell fusion.
Nature biotechnology 2004;22(3):331-6.
2004: Dingli David; Peng Kah-Whye; Harvey Mary E; Greipp Philip R; O'Connor Michael K; Cattaneo Roberto; Morris John C; Russell Stephen J
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.
Blood 2004;103(5):1641-6.
2003: Russell Stephen J; Peng Kah-Whye
Primer on medical genomics. Part X: Gene therapy.
Mayo Clinic proceedings. Mayo Clinic 2003;78(11):1370-83.
2003: Peng Kah-Whye; Frenzke Marie; Myers Rae; Soeffker Diane; Harvey Mary; Greiner Suzanne; Galanis Evanthia; Cattaneo Roberto; Federspiel Mark J; Russell Stephen J
Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice.
Human gene therapy 2003;14(16):1565-77.
2003: Phuong Loi K; Allen Cory; Peng Kah-Whye; Giannini Caterina; Greiner Suzanne; TenEyck Cynthia J; Mishra Prasanna K; Macura Slobodan I; Russell Stephen J; Galanis Evanthia C
Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
Cancer research 2003;63(10):2462-9.
2003: Johnson K J; Peng K-W; Allen C; Russell S J; Galanis E
Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
Gene therapy 2003;10(9):725-32.
2003: Peng Kah-Whye; Donovan Kathleen A; Schneider Urs; Cattaneo Roberto; Lust John A; Russell Stephen J
Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker.
Blood 2003;101(7):2557-62.
2002: Peng Kah-Whye; TenEyck Cynthia J; Galanis Evanthia; Kalli Kimberly R; Hartmann Lynn C; Russell Stephen J
Intraperitoneal therapy of ovarian cancer using an engineered measles virus.
Cancer research 2002;62(16):4656-62.
2002: Peng Kah-Whye; Facteau Suzanne; Wegman Troy; O'Kane Dennis; Russell Stephen J
Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides.
Nature medicine 2002;8(5):527-31.
2001: Peng K W; Pham L; Ye H; Zufferey R; Trono D; Cosset F L; Russell S J
Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors.
Gene therapy 2001;8(19):1456-63.
2001: Peng K W; Ahmann G J; Pham L; Greipp P R; Cattaneo R; Russell S J
Systemic therapy of myeloma xenografts by an attenuated measles virus.
Blood 2001;98(7):2002-7.
2001: Pham L; Ye H; Cosset F L; Russell S J; Peng K W
Concentration of viral vectors by co-precipitation with calcium phosphate.
The journal of gene medicine 2001;3(2):188-94.
1999: Peng K W; Russell S J
Viral vector targeting.
Current opinion in biotechnology 1999;10(5):454-7.
1999: Peng K W
Strategies for targeting therapeutic gene delivery.
Molecular medicine today 1999;5(10):448-53.
1999: Peng K W; Vile R; Cosset F L; Russell S
Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors.
Gene therapy 1999;6(9):1552-7.
1996: Ager S; Nilson B H; Morling F J; Peng K W; Cosset F L; Russell S J
Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity.
Human gene therapy 1996;7(17):2157-64.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Kah-Whye Peng

Research Profile (preview)

Living Beings

Chemicals & Drugs

Anatomy

Procedures

Disorders

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Kah-Whye Peng (preview)

All Publications